Table 2.

Univariate and multivariate analyses of early stage MSI CRCs.

	Overall survival				Disease-free survival
	Univariate*		Multivariate*		Univariate*		Multivariate*
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Gender (male vs. female)	0.74 (0.41–1.28)	0.2861			0.76 (0.43–1.30)	0.3135
Age (>65 vs. ≤ 65)	3.46 (1.83–7.11)	0.0001	3.27 (1.73–6.74)	0.0001	3.21 (1.74–6.39)	0.0001	3.04 (1.65–6.08)	0.0002
Tumor location (right vs. left)	1.71 (0.85–3.97)	0.1422			1.50 (0.76–3.31)	0.2550
Histology (mucinous vs. others)	0.49 (0.17–1.12)	0.0975			0.46 (0.16–1.05)	0.0683
Tumor grade (G3 vs. G1/2)	1.06 (0.53–1.98)	0.8509			1.11 (0.57–2.04)	0.7348
Tumor stage (II vs. I)	1.46 (0.83–2.64)	0.1932			1.38 (0.80–2.48)	0.2464
Maspin expression (high vs. low)	0.39 (0.17–0.79)	0.0076	0.43 (0.18–0.88)	0.0184	0.37 (0.16–0.74)	0.0038	0.39 (0.17–0.80)	0.0085

^*Cox proportional hazards model. HR, hazard ratio; CI, confidence interval.